Aquinox Announces First Quarter 2017 Financial Results Post author:Sam Post published:May 8, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Outgoing Novartis CEO Hunts for His Next Big Challenge January 24, 2018 Janssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Years Of Follow-Up June 4, 2017 Takeda's $5 Billion Bet on Ariad Pays Off With Accelerated Approval of Lung Cancer Med April 30, 2017
Janssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Years Of Follow-Up June 4, 2017
Takeda's $5 Billion Bet on Ariad Pays Off With Accelerated Approval of Lung Cancer Med April 30, 2017